Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Shigella sonnei O-specific polysaccharide (O-SP) is the outermost domain of the lipopolysaccharide (LPS) molecule found on the surface of S. sonnei. It plays a dual role as both an essential virulence factor and a protective antigen. The O-SP consists of repeating oligosaccharide units of 2-acetamido-2-deoxy-L-altruronic acid (L-AltNAcA) and 2-acetamido-4-amino-2,4-dideoxy-D-fucose (FucNAc4N). It is a primary target for immune responses and vaccine development against shigellosis. Conjugation of the O-SP to carrier proteins enhances immunogenicity.
Antibody neutralization, complement activation prevention
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shigella sonnei O-specific Polysaccharide (None).